Pasithea Therapeutics Corp.
Close on Oct 19, 2026
- Market cap
- $13.23M
- P/E (TTM)
- –
- Dividend yield
- –
About Pasithea Therapeutics
Pharmaceutical Preparations, SIC 2834
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company engaged in discovering, researching, and developing therapeutic treatments. Its drug development pipeline primarily focuses on small molecule therapies for RASopathies, tumors driven by the MAPK pathway, and central nervous system disorders. The company's lead therapeutic product candidate is PAS-004, a next-generation macrocyclic MEK 1/2 inhibitor being evaluated for advanced solid tumors and neurofibromatosis type 1, including plexiform neurofibromas. Additionally, the company conducts early-stage research on its PAS-001 program, which targets complement component 4A for schizophrenia.
As a clinical-stage development enterprise, the company does not operate commercial sales facilities and aims to develop treatments for patients with high unmet medical needs. Clinical trials for its lead drug candidate take place across multiple international locations, including study sites in the United States, Eastern Europe, Australia, and South Korea. Pasithea Therapeutics Corp. is incorporated in Delaware and maintains its principal executive offices in Miami Beach, Florida.
Summary of the business section of Pasithea Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Pasithea Therapeutics Corp.
- Headquarters
- Miami Beach, FL
- Address
- 1111 Lincoln Road, Suite 500 33139
- Phone
- (702) 514-4174
- Website
- pasithea.com
- Employees
- 5, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- CBIZ CPAs P.C., Hartford, Connecticut
Stock & identifiers
- Ticker
- KTTA
- Exchange
- Nasdaq
- IPO date
- Sep 16, 2021
- Shares outstanding
- 33M, Aug 12, 2026
- Public float
- $5.10M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-20 reverse, Mar 29, 2024; 1-for-20 reverse, Jan 2, 2024
- SEC CIK
- 1841330
- CUSIP
- 70261F202
- ISIN
- US70261F2020
- EIN
- 85-1591963
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Tiago Marques | Chief Executive Officer, Director | 73,334 |
| Kartik Krishnan | Chief Medical Officer | – |
| Daniel H. Schneiderman | Chief Financial Officer | 26,667 |
| Simon Dumesnil | Director | 35,833 |
| Lawrence Steinman | Director | 199,691 |
| Alfred J. Novak | Director | 3,500 |
| Emer Leahy | Director | 33,333 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had five full-time employees.”
Corporate history
Events identified from SEC filings